Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2022.04.11.22273729: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Institutional Review Board of Erlangen University Hospital (
Consent: #157_20 B), and written informed consent was obtained from all study participants.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Setting and Cohort: IMID patients and healthy controls (HC) were recruited from the prospective COVID-19 study program conducted by the Deutsche Zentrum fuer Immuntherapie, which since February 2020 has collected data on respiratory infections including COVID-19 as well as anti-SARS-CoV-2 antibody responses before and after the vaccination era and … SciScore for 10.1101/2022.04.11.22273729: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was approved by the Institutional Review Board of Erlangen University Hospital (
Consent: #157_20 B), and written informed consent was obtained from all study participants.Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Table 2: Resources
Antibodies Sentences Resources Setting and Cohort: IMID patients and healthy controls (HC) were recruited from the prospective COVID-19 study program conducted by the Deutsche Zentrum fuer Immuntherapie, which since February 2020 has collected data on respiratory infections including COVID-19 as well as anti-SARS-CoV-2 antibody responses before and after the vaccination era and exposure risk behavior over time. anti-SARS-CoV-2suggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has some limitations. We have collected serum samples in an unscheduled timeline along the routine care of IMID patients, this may have resulted in more frequent or diligent sampling in IMID patients who get to visit the clinic more frequently. To mitigate this potential bias, we have used regression methods that account for within patient correlations using random effects. Samples from IMID patients were obtained predominantly under cytokine blocking treatments, therefore the overall between-group comparisons should reflect the weight of this treatment class, which affects the generalizability of our results. On the other hand, we also observe similar differences between IMID patients not receiving any immunomodulating treatment and HC. We did not attempt to separate the effects of treatments independent of diseases or antibody response across disease activity states, therefore the antibody levels reported here could be considered as average effects of treatments combined with the variety of diseases they are used for or similarly as average effects of diagnoses combined with their routine treatment patterns. We did not collect data on corticosteroid doses, however higher dosed corticosteroid treatments are usually given in combination with cytotoxic agents in conditions such as lupus nephritis or ANCA associated vasculitis. Therefore, their effects could be considered as embedded within those treatment categories and participants using only corticosteroid treatmen...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
-
